Trials / Completed
CompletedNCT04249284
Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants
A Study to Evaluate the Pharmacokinetics of BMS-986165 Administered as Various Prototypic Solid Tablet Formulations in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to characterize the pharmacokinetics (the way the body absorbs, distributes and eliminates the drug) of BMS 986165 given in the form of various prototypes of solid tablets to healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986165 | Specified dose on specified days |
| DRUG | BMS-986165 prototype 1 | Specified dose on specified days |
| DRUG | BMS-986165 prototype 2 | Specified dose on specified days |
Timeline
- Start date
- 2020-02-06
- Primary completion
- 2020-03-15
- Completion
- 2020-03-15
- First posted
- 2020-01-30
- Last updated
- 2020-04-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04249284. Inclusion in this directory is not an endorsement.